
Travere Therapeutics (TVTX) Stock Forecast & Price Target
Travere Therapeutics (TVTX) Analyst Ratings
Bulls say
Travere Therapeutics is expected to report strong results in the second quarter of 2026, with total revenue of $170 million beating both consensus and Wall Street estimates. Despite an initial loss due to a convertible note expense, the company has a strong cash position and a promising pipeline candidate in sparsentan, making it a valuable investment with potential for significant growth. Additionally, the company's recent patent extension for Filspari in the IgAN indication provides added exclusivity until 2037, increasing the stock's target price to $75. The impending FDA alignment for pegtibatinase and the potential for Filspari to work in conjunction with newer agents in the market also lend additional support to the company's position. However, potential delays or setbacks in commercializing their products, as well as the need for future capital raises, are potential risks to consider when investing in Travere Therapeutics.
Bears say
Travere Therapeutics is a biopharmaceutical company with a focus on developing therapies for rare kidney, liver, and metabolic diseases. Despite strong initial momentum following the launch of Filspari for FSGS, the latest quarterly figures showed a significant slowdown in patient start forms, potentially indicating a potential slowdown in demand. Additionally, the company's increased SG&A expenses and continued reliance on a single product for revenue make us cautious about its long-term prospects.
This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares